

**CB1 Receptor Rabbit mAb [25P0]**

**Cat NO. :A94301**

**Information:**

Applications	Reactivity:	UniProt ID:	MW(kDa)	Host	Isotype	Size
WB	H,M,R	P21554	60 kDa	Rabbit	IgG	100ul,200ul

**Applications detail:**

Application	Dilution
WB	1:1000-2000
The optimal dilutions should be determined by the end user	

**Conjugate:**

UnConjugate

**Form:**

Liquid

**sensitivity:**

Endogenous

**Purification:**

Protein A purification

**Specificity:**

Antibody is produced by immunizing animals with a synthetic peptide at the sequence of Human CB1 Receptor

**Storage buffer and conditions:**

Antibody store in 10 mM PBS, 0.5mg/ml BSA, 50% glycerol (buffer) .

Shipped at 4°C. Store at-20°C or -80°C.

Products are valid for one natural year of receipt.Avoid repeated freeze / thaw cycles.

**Tissue specificity:**

Widely expressed, with highest levels in fetal and adult brain. Expression levels of isoform 2 and isoform 3 are much lower than those of isoform 1..

**Subcellular location:**

Cell membrane,Multi-pass membrane protein. Membrane raft. Mitochondrion outer membrane. Cell projection, axon. Cell junction, synapse, presynapse.

**Function:**

**Introduction:** **WB:** Western Blot **IP:** Immunoprecipitation **IHC:** Immunohistochemistry **ChIP:** Chromatin Immunoprecipitation **ICC/IF:** Immunocytochemistry/Immunofluorescence **F:** Flow Cytometry


**Cross Reactivity:** **H:** human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Ml:** mink **C:** chicken **Dm** D. melanogaster **X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Hr:** horse

**For Research Use Only. Not For Use In Diagnostic Procedures.**

G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC) (PubMed:15620723, PubMed:27768894, PubMed:27851727). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP (PubMed:1718258, PubMed:21895628, PubMed:27768894). In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylylase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner (PubMed:17895407). In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesterol uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of

## Validation Data:

### CB1 Receptor Rabbit mAb [25P0] Images



Western blot (SDS PAGE) analysis of extracts from Rat brain. Using CB1 Receptor Rabbit mAb [25P0] at dilution of 1:1000 incubated at 4°C over night.

View more information on <http://naturebios.com>

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 1% w/v Milk, 1X TBST at 4°C overnight.